Clinical Trial

Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-02.
Status change: Not Yet Recruiting → Recruiting 2025-01-21
Trial Details
NCT Number NCT06351150
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Vasodilatory Shock
Enrollment 214 participants
Start Date 2024-07-23
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-23